Skip to content
PubMed This is a summary of 10 peer-reviewed journal articles Updated
Neurology · Dopamine Agonist Withdrawal Syndrome

What Is Dopamine Agonist Withdrawal Syndrome in RLS?

At a Glance

Dopamine agonist withdrawal syndrome (DAWS) is a withdrawal reaction after these RLS medicines are reduced or stopped. It may cause severe mood changes, anxiety, fatigue, pain, sweating, tremors, and restlessness, so tapering should be gradual and medically supervised.

If you are experiencing severe physical and emotional distress while trying to reduce or stop a dopamine agonist like ropinirole, pramipexole, or rotigotine, your experience is valid. Many people develop significant withdrawal symptoms during this transition [1]. Because the nervous system adapts to these medications over time, reducing the dose can trigger a recognized but complex reaction known as Dopamine Agonist Withdrawal Syndrome (DAWS) [1].

Important Safety Warning: While mood changes can occur during withdrawal, severe depression, panic, confusion, or thoughts of self-harm are medical emergencies. Do not dismiss these as “just withdrawal.” If you experience suicidal thoughts or feel you cannot stay safe, contact your prescriber immediately, call a local crisis line, or go to an emergency room. Do not stay alone while waiting for help.

Understanding DAWS, Augmentation, and Rebound

When transitioning off dopamine agonists, symptoms can overlap. It is important to work with your doctor to identify what is happening, as they require different management strategies:

  • Augmentation: A long-term worsening of RLS caused by the medication itself. Symptoms may start earlier in the day, become more intense, or spread to the arms and trunk [2]. This is often the primary reason patients need to stop the drug.
  • Rebound RLS: A temporary, intense flare-up of RLS symptoms that happens as a single dose wears off or immediately after a dose is reduced [3].
  • DAWS (Withdrawal Syndrome): A distinct reaction to lowering or stopping the medication. While heavily studied in Parkinson’s disease, DAWS has also been reported in people treated for RLS [1].

Symptoms of Withdrawal

Withdrawal from dopamine agonists can cause a range of intense, distressing symptoms [1]. Because much of the evidence for DAWS comes from Parkinson’s disease research, the exact frequency and diagnostic criteria for RLS patients are still being studied [1][4]. Reported symptoms include:

  • Psychological distress: Severe depression, extreme anxiety, panic attacks, agitation, and apathy (a lack of interest or emotion) [1][4].
  • Physical symptoms: Profound fatigue, generalized pain, sweating, tremors, and unexpected “electric-like” sensations [1][5].
  • Restlessness: Akathisia (a severe, uncontrollable inner restlessness) which can be difficult to distinguish from rebound RLS [1].

(Note: Nausea can occur during withdrawal, but it can also be a side effect of active medication or other illnesses [6]. Any new, severe, or unusual symptoms—especially severe nausea accompanied by vomiting or dehydration—should be reported to your prescriber for evaluation).

Safely Tapering Your Medication

Because abrupt changes can trigger severe withdrawal and marked RLS flare-ups, you should generally never stop your medication abruptly or change your dose without medical supervision [1][3]. Tapering must be highly individualized.

1. Considering Replacement Medications (Bridging)

To help ease the transition, doctors often introduce a new RLS medication before you begin lowering your dopamine agonist dose [3]. The choice of replacement depends on your kidney function, age, risk for sleep apnea, and other health factors. Common options include:

  • Alpha-2-delta ligands: Medications like gabapentin, gabapentin enacarbil, or pregabalin are often preferred [2][7]. Safety note: These medications can cause dizziness, sleepiness, weight gain, and—when combined with other sedatives—breathing problems [7].
  • Low-dose opioids: For carefully assessed, refractory cases of RLS where other treatments fail, specialists may prescribe low-dose opioids (like oxycodone or methadone) [8][9]. Safety note: Opioids carry serious risks of dependence, overdose, severe constipation, and respiratory depression, especially if you have sleep apnea or use alcohol or other sedating drugs [10]. They require strict monitoring by an experienced clinician.

2. A Slow, Individualized Taper

There is no single validated schedule for every drug and dose. Once a replacement medication is working, your doctor will likely lower your dopamine agonist dose very gradually [3]. This process may require pauses or adjustments to allow time to assess your response. If symptoms become unmanageable, contact your prescriber promptly. Do not reinstate, increase, or substitute medications on your own.

3. Evaluating Underlying Factors

Before or during your taper, your doctor should evaluate your iron levels (ferritin and transferrin saturation). While clinical interpretation is required (as ferritin can be misleading if inflammation is present), treating true iron deficiency can improve RLS symptoms, though it does not guarantee prevention of DAWS [2].

Additionally, review all your medications with your doctor. Certain drugs—like sedating antihistamines or some antidepressants—can make RLS worse [2]. However, do not stop taking any prescribed medication, especially antidepressants, without consulting your pharmacist or prescriber first.

Common questions in this guide

What is dopamine agonist withdrawal syndrome in RLS?
DAWS is a withdrawal reaction that may happen when an RLS dopamine agonist such as ropinirole, pramipexole, or rotigotine is reduced or stopped. It can cause intense emotional and physical symptoms in addition to a flare of restless legs symptoms.
How is DAWS different from augmentation and rebound RLS?
Augmentation is a long-term worsening caused by the dopamine agonist, such as symptoms starting earlier, becoming stronger, or spreading beyond the legs. Rebound RLS is a temporary flare as a dose wears off or is reduced, while DAWS can include broader mood and physical withdrawal symptoms. A prescriber should help distinguish them because management differs.
What symptoms can occur when I taper a dopamine agonist?
Possible symptoms include severe depression, anxiety, panic, agitation, apathy, profound fatigue, pain, sweating, tremors, electric-like sensations, and severe inner restlessness. Nausea can also occur, but new or severe symptoms should be reported to the prescriber because they may have another cause.
How can dopamine agonists be tapered safely for RLS?
Do not stop or change the dose abruptly or without medical supervision. A clinician may first introduce a replacement treatment, then reduce the dopamine agonist slowly with pauses or adjustments based on your symptoms. Do not restart, increase, or substitute medication on your own.
What medicines may bridge the taper?
Doctors may consider gabapentin, gabapentin enacarbil, or pregabalin, depending on kidney function, age, sleep apnea risk, and other health factors. Low-dose opioids may be considered only for carefully assessed, refractory RLS and require close specialist monitoring because of dependence, overdose, constipation, and breathing risks.
When should withdrawal symptoms be treated as an emergency?
Severe depression, panic, confusion, or thoughts of self-harm are emergencies and should not be dismissed as routine withdrawal. Contact your prescriber immediately, call a local crisis line, or go to an emergency department, and do not stay alone while waiting for help.
Should iron levels and other medicines be checked during a taper?
Your clinician may check ferritin and transferrin saturation and treat confirmed iron deficiency to improve RLS symptoms, although this does not guarantee prevention of DAWS. Ask a pharmacist or prescriber to review antihistamines, sleep aids, antidepressants, and other medicines that may worsen RLS, and do not stop prescribed medicines on your own.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What specific, step-by-step tapering schedule do you recommend, and how will we adjust it if my withdrawal symptoms become severe?
  2. 2.Are there replacement medications (like gabapentin or pregabalin) that might help bridge the gap, and what are their specific risks for me?
  3. 3.How will we monitor for side effects like sedation or breathing issues if we start a new medication?
  4. 4.Can we check a complete iron panel (ferritin and transferrin saturation) to see if underlying iron deficiency is worsening my RLS?
  5. 5.Who is my specific after-hours contact, and what is our plan if I experience a psychiatric emergency or unmanageable rebound symptoms?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (10)
  1. 1

    Case Report: Prolonged DAWS in an RLS patient under severe relational stress.

    Gillon M

    Frontiers in human neuroscience 2025; (19()):1613710 doi:10.3389/fnhum.2025.1613710.

    PMID: 41601611
  2. 2

    Guidelines for the first-line treatment of restless legs syndrome/Willis-Ekbom disease, prevention and treatment of dopaminergic augmentation: a combined task force of the IRLSSG, EURLSSG, and the RLS-foundation.

    Garcia-Borreguero D, Silber MH, Winkelman JW, et al.

    Sleep medicine 2016; (21()):1-11.

    PMID: 27448465
  3. 3

    Treating Severe Refractory and Augmented Restless Legs Syndrome.

    Winkelman JW

    Chest 2022; (162(3)):693-700 doi:10.1016/j.chest.2022.05.014.

    PMID: 35609673
  4. 4

    Rasagiline Withdrawal Syndrome in Parkinson's Disease.

    Solla P, Ercoli T, Masala C, et al.

    Brain sciences 2022; (12(2)) doi:10.3390/brainsci12020219.

    PMID: 35203982
  5. 5

    A Pilot Prospective, Multicenter Observational Study of Dopamine Agonist Withdrawal Syndrome in Parkinson's Disease.

    Chaudhuri KR, Todorova A, Nirenberg MJ, et al.

    Movement disorders clinical practice 2015; (2(2)):170-174 doi:10.1002/mdc3.12141.

    PMID: 30713891
  6. 6

    Prevalence of Nausea and Vomiting in Adults Using Ropinirole: A Systematic Review and Meta-Analysis.

    Kurin M, Bielefeldt K, Levinthal DJ

    Digestive diseases and sciences 2018; (63(3)):687-693 doi:10.1007/s10620-018-4937-3.

    PMID: 29383607
  7. 7

    Treatment response to sleep, pain, and mood disturbance and their correlation with sleep disturbance in adult patients with moderate-to-severe primary restless legs syndrome: Pooled analyses from 3 trials of gabapentin enacarbil.

    Bogan RK, Lee DO, Buchfuhrer MJ, et al.

    Annals of medicine 2015; (47(3)):269-77 doi:10.3109/07853890.2015.1025825.

    PMID: 25874578
  8. 8

    Treatment of restless legs syndrome and periodic limb movement disorder: an American Academy of Sleep Medicine clinical practice guideline.

    Winkelman JW, Berkowski JA, DelRosso LM, et al.

    Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine 2025; (21(1)):137-152 doi:10.5664/jcsm.11390.

    PMID: 39324694
  9. 9

    The Appropriate Use of Opioids in the Treatment of Refractory Restless Legs Syndrome.

    Silber MH, Becker PM, Buchfuhrer MJ, et al.

    Mayo Clinic proceedings 2018; (93(1)):59-67 doi:10.1016/j.mayocp.2017.11.007.

    PMID: 29304922
  10. 10

    Long-term Safety, Dose Stability, and Efficacy of Opioids for Patients With Restless Legs Syndrome in the National RLS Opioid Registry.

    Winkelman JW, Wipper B, Zackon J

    Neurology 2023; (100(14)):e1520-e1528 doi:10.1212/WNL.0000000000206855.

    PMID: 36697248

This page about DAWS in RLS is for informational purposes only and does not constitute medical advice. Do not change or stop a dopamine agonist without your prescriber, and seek immediate help for suicidal thoughts or feeling unsafe.

Get notified when new evidence is published on Restless Legs Syndrome.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.